Wu Mei-Zhen, Teng Tiew-Hwa Katherine, Tay Wan-Ting, Ren Qing-Wen, Tromp Jasper, Ouwerkerk Wouter, Chandramouli Chanchal, Huang Jia-Yi, Chan Yap-Hang, Teramoto Kanako, Yu Si-Yeung, Lawson Claire, Li Hang-Long, Tse Yi-Kei, Li Xin-Li, Hung Denise, Tse Hung-Fat, Lam Carolyn S P, Yiu Kai-Hang
Division of Cardiology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shen Zhen, China.
Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Diabetes Obes Metab. 2023 Mar;25(3):707-715. doi: 10.1111/dom.14916. Epub 2022 Nov 29.
To investigate the interplay of incident chronic kidney disease (CKD) and/or heart failure (HF) and their associations with prognosis in a large, population-based cohort with type 2 diabetes (T2DM).
Patients aged ≥18 years with new-onset T2DM, without renal disease or HF at baseline, were identified from the territory-wide Clinical Data Analysis Reporting System between 2000 and 2015. Patients were followed up until December 31, 2020 for incident CKD and/or HF and all-cause mortality.
Among 102 488 patients (median age 66 years, 45.7% women, median follow-up 7.5 years), new-onset CKD occurred in 14 798 patients (14.4%), in whom 21.7% had HF. In contrast, among 9258 patients (9.0%) with new-onset HF, 34.6% had CKD. The median time from baseline to incident CKD or HF (4.4 vs. 4.1 years) did not differ. However, the median (interquartile range) time until incident HF after CKD diagnosis was 1.7 (0.5-3.6) years and was 1.2 (0.2-3.4) years for incident CKD after HF diagnosis (P < 0.001). The crude incidence of CKD was higher than that of HF: 17.6 (95% confidence interval [CI] 17.3-17.9) vs. 10.6 (95% CI 10.4-10.9)/1000 person-years, respectively, but incident HF was associated with a higher adjusted-mortality than incident CKD. The presence of either condition (vs. CKD/HF-free status) was associated with a three-fold hazard of death, whereas concomitant HF and CKD conferred a six to seven-fold adjusted hazard of mortality.
Cardiorenal complications are common and are associated with high mortality risk among patients with new-onset T2DM. Close surveillance of these dual complications is crucial to reduce the burden of disease.
在一个大型的、基于人群的2型糖尿病(T2DM)队列中,研究新发慢性肾脏病(CKD)和/或心力衰竭(HF)之间的相互作用及其与预后的关系。
从2000年至2015年的全港临床数据分析报告系统中,识别出年龄≥18岁、新发T2DM、基线时无肾脏疾病或HF的患者。对患者进行随访直至2020年12月31日,以观察新发CKD和/或HF以及全因死亡率。
在102488例患者中(中位年龄66岁,45.7%为女性,中位随访7.5年),14798例患者(14.4%)发生了新发CKD,其中21.7%患有HF。相比之下,在9258例新发HF患者中(9.0%),34.6%患有CKD。从基线到新发CKD或HF的中位时间(4.4年对4.1年)无差异。然而,CKD诊断后至新发HF的中位(四分位间距)时间为1.7(0.5 - 3.6)年,HF诊断后至新发CKD的时间为1.2(0.2 - 3.4)年(P < 0.001)。CKD的粗发病率高于HF:分别为17.6(95%置信区间[CI] 17.3 - 17.9)对10.6(95% CI 10.4 - 10.9)/1000人年,但新发HF比新发CKD与更高的校正死亡率相关。两种情况中的任何一种(与无CKD/HF状态相比)都与三倍的死亡风险相关,而同时存在HF和CKD则使校正后的死亡风险增加六至七倍。
心肾并发症在新发T2DM患者中很常见,且与高死亡风险相关。密切监测这些双重并发症对于减轻疾病负担至关重要。